A biomarker analysis of plasma and tumor DNA in afatinib-treatedpatients with EGFR mutation-positive advanced adenocarcinoma of the lung.

Trial Profile

A biomarker analysis of plasma and tumor DNA in afatinib-treatedpatients with EGFR mutation-positive advanced adenocarcinoma of the lung.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 May 2016

At a glance

  • Drugs Afatinib (Primary)
  • Indications Adenocarcinoma
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic
  • Acronyms Afatinib I I S
  • Most Recent Events

    • 15 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 09 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top